170 related articles for article (PubMed ID: 37439934)
1. Improved performance of non-preloaded and high flip-angle dynamic susceptibility contrast perfusion-weighted imaging sequences in the presurgical differentiation of brain lymphoma and glioblastoma.
Wang F; Zhou X; Chen R; Kang J; Yang X; Lin J; Liu F; Cao D; Xing Z
Eur Radiol; 2023 Dec; 33(12):8800-8808. PubMed ID: 37439934
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric analysis from dynamic susceptibility contrast-enhanced perfusion MRI to evaluate malignant brain tumors.
Abreu VS; Tarrio J; Silva J; Almeida F; Pinto C; Freitas D; Filipe JP
J Neuroimaging; 2024; 34(2):257-266. PubMed ID: 38173078
[TBL] [Abstract][Full Text] [Related]
3. Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRI.
Kang KM; Choi SH; Chul-Kee P; Kim TM; Park SH; Lee JH; Lee ST; Hwang I; Yoo RE; Yun TJ; Kim JH; Sohn CH
Eur Radiol; 2021 Dec; 31(12):9098-9109. PubMed ID: 34003350
[TBL] [Abstract][Full Text] [Related]
4. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
[TBL] [Abstract][Full Text] [Related]
5. MR dynamic-susceptibility-contrast perfusion metrics in the presurgical discrimination of adult solitary intra-axial cerebellar tumors.
Pons-Escoda A; Garcia-Ruiz A; Garcia-Hidalgo C; Gil-Solsona R; Naval-Baudin P; Martin-Noguerol T; Fernandez-Coello A; Flores-Casaperalta S; Fernandez-Viñas M; Gago-Ferrero P; Oleaga L; Perez-Lopez R; Majos C
Eur Radiol; 2023 Dec; 33(12):9120-9129. PubMed ID: 37439938
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of Primary Central Nervous System Lymphoma and High-Grade Glioma with Dynamic Susceptibility Contrast-Derived Metrics: Pilot Study.
Chaganti J; Taylor M; Woodford H; Steel T
World Neurosurg; 2021 Jul; 151():e979-e987. PubMed ID: 34020062
[TBL] [Abstract][Full Text] [Related]
8. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
[TBL] [Abstract][Full Text] [Related]
9. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging.
Kickingereder P; Wiestler B; Sahm F; Heiland S; Roethke M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Radiology; 2014 Sep; 272(3):843-50. PubMed ID: 24814181
[TBL] [Abstract][Full Text] [Related]
10. Validation of combined use of DWI and percentage signal recovery-optimized protocol of DSC-MRI in differentiation of high-grade glioma, metastasis, and lymphoma.
Cindil E; Sendur HN; Cerit MN; Dag N; Erdogan N; Celebi FE; Oner Y; Tali T
Neuroradiology; 2021 Mar; 63(3):331-342. PubMed ID: 32821962
[TBL] [Abstract][Full Text] [Related]
11. Percentage signal intensity recovery: A step ahead of rCBV in DSC MR perfusion imaging for the differentiation of common neoplasms of brain.
Surendra KL; Patwari S; Agrawal S; Chadaga H; Nagadi A
Indian J Cancer; 2020; 57(1):36-43. PubMed ID: 31898591
[TBL] [Abstract][Full Text] [Related]
12. Investigating dynamic susceptibility contrast-enhanced perfusion-weighted magnetic resonance imaging in posterior fossa tumors: differences and similarities with supratentorial tumors.
Gaudino S; Benenati M; Martucci M; Botto A; Infante A; Marrazzo A; Ramaglia A; Marziali G; Guadalupi P; Colosimo C
Radiol Med; 2020 Apr; 125(4):416-422. PubMed ID: 31916104
[TBL] [Abstract][Full Text] [Related]
13. Differentiation between primary CNS lymphoma and glioblastoma: qualitative and quantitative analysis using arterial spin labeling MR imaging.
You SH; Yun TJ; Choi HJ; Yoo RE; Kang KM; Choi SH; Kim JH; Sohn CH
Eur Radiol; 2018 Sep; 28(9):3801-3810. PubMed ID: 29619520
[TBL] [Abstract][Full Text] [Related]
14. Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma.
Lee B; Park JE; Bjørnerud A; Kim JH; Lee JY; Kim HS
AJNR Am J Neuroradiol; 2018 Aug; 39(8):1415-1422. PubMed ID: 30026384
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
Xing Z; You RX; Li J; Liu Y; Cao DR
Clin Neuroradiol; 2014 Dec; 24(4):329-36. PubMed ID: 23994941
[TBL] [Abstract][Full Text] [Related]
16. Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI.
Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
Clin Radiol; 2015 Dec; 70(12):1393-9. PubMed ID: 26382744
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction.
Toh CH; Wei KC; Chang CN; Ng SH; Wong HF
AJNR Am J Neuroradiol; 2013; 34(6):1145-9. PubMed ID: 23348763
[TBL] [Abstract][Full Text] [Related]
18. Voxel-level analysis of normalized DSC-PWI time-intensity curves: a potential generalizable approach and its proof of concept in discriminating glioblastoma and metastasis.
Pons-Escoda A; Garcia-Ruiz A; Naval-Baudin P; Grussu F; Fernandez JJS; Simo AC; Sarro NV; Fernandez-Coello A; Bruna J; Cos M; Perez-Lopez R; Majos C
Eur Radiol; 2022 Jun; 32(6):3705-3715. PubMed ID: 35103827
[TBL] [Abstract][Full Text] [Related]
19. MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Park JE; Choi CG; Kim SJ
J Magn Reson Imaging; 2019 Aug; 50(2):560-572. PubMed ID: 30637843
[TBL] [Abstract][Full Text] [Related]
20. Systematic assessment of multi-echo dynamic susceptibility contrast MRI using a digital reference object.
Stokes AM; Semmineh NB; Nespodzany A; Bell LC; Quarles CC
Magn Reson Med; 2020 Jan; 83(1):109-123. PubMed ID: 31400035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
